Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 Biomarker phenotype BEFREE The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. 25907102 2016
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 GeneticVariation phenotype BEFREE In conclusion, MRD monitoring early after transplant allows further rapid identification of t(8;21) patients at high risk of relapse and was more predictive of relapse risk than c-KIT mutations. 25082877 2014
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 Biomarker phenotype BEFREE To improve MRD assessment by MFC, we here evaluate the combination of human Myeloid Inhibitory C-type Lectin (hMICL, also termed C-type lectin domain family 12, member A, CLEC12A) and CD 123 (also termed interleukin-3 receptor alpha, IL3RA) in combination with CD34 and CD117 (KIT), as an MRD assay in pre-clinical and clinical testing in 69 AML patients. 24152218 2014
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 GeneticVariation phenotype BEFREE Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual disease (MRD) levels, but their respective values have never been prospectively assessed. 23321257 2013
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 Biomarker phenotype BEFREE Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. 19603346 2009
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 Biomarker phenotype BEFREE Our results indicate that quantitative analysis of CD34 and CD117 may be useful to detect minimal residual disease (MRD) and could be tested in a future to monitor therapy in AML. 12008077 2002
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.070 Biomarker phenotype BEFREE It has been suggested that CD117 in combination with other antigens may be of great help for the identification of leukemia-associated phenotypes that could be used to monitor MRD in both acute myeloid leukemias and multiple myeloma patients achieving morphological complete remission. 9711908 1998